spawns/iStock via Getty Images
Insmed (INSM) shares traded higher on Friday after the rare disease drug developer announced preliminary unaudited revenue for 2025, exceeding Wall Street forecasts ahead of a presentation at the upcoming Annual J.P. Morgan Healthcare Conference.
The Bridgewater, New Jersey-based biotech expects